Company intelligence / Profile preview

NeuroPro Therapeutics

Ownership: Private
Development stage: Phase 2

Overview

NeuroPro’s lead candidate NPT 2042 has shown proof-of-efficacy in preclinical models similar to bumetanide and furosemide but without diuretic side effects. The compound targets abnormal neuronal hypersynchrony via glial cell NKCC antagonism, aiming to control seizures more effectively and with fewer cognitive/neurological side effects than current anti-seizure medications. Clinical trials are underway or imminent as of early 2025

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

NPT-2042

1 more asset in the full pipeline.

Request access →

Partnerships

No major pharmaceutical partnerships publicly disclosed; funded by a prominent equity fund since 2019 and previously by angel investors[2]. Open to provider/investor partnerships[5].

Beyond the preview

Go deeper on NeuroPro Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroPro Therapeutics.

Explore the full profile